Disclaimer: This is an early beta prototype. If you find any error, with data or functionality, please let us know via this page.
OSP finalist
Open Knowledge
Advanced search
Action period

  1. Summary Review

    Action date:
    FDA Application:
    NDA205625
    Drug:
    Arnuity ellipta
    Active Ingredients:
    Fluticasone furoate
    • ...CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 2056250rig15000 SUMMARY REVIEW...
    • ...SUMMARY REVIEW OF REGULATORY ACTION Date: August 20, 2014 From: Badrul A. Chowdhury, MD, PhD Director, Division of Pulmonary, Allergy...

  2. Label

    Action date:
    FDA Application:
    NDA205613
    Drug:
    Uceris
    Active Ingredients:
    Budesonide
    • ...• HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use UCERIS rectal foam safely and effectively...
    • ...FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE UCERIS rectal foam is indicated for the induction of remission in patients with active mild...

  3. Letter

    Action date:
    FDA Application:
    NDA205613
    Drug:
    Uceris
    Active Ingredients:
    Budesonide
    • ...DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Silver Spring MD 20993 NDA 205613 NDA APPROVAL Salix Pharmaceuticals, Inc...
    • ...NDA 205613 Page 2 The SPL will be accessible via publicly available labeling repositories. CARTON AND IMMEDIATE CONTAINER LABELS We acknowledge your...

  4. Summary Review

    Action date:
    FDA Application:
    NDA205613
    Drug:
    Uceris
    Active Ingredients:
    Budesonide
    • ...CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 2056130rig15000 SUMMARY REVIEW...
    • ...Deputy Division Director Review NBA 2056] 3 Uceris (budesonide) rectal foam 2 mg September 15, 2014 Summary Review for Regulatory Action...

  5. Label

    Action date:
    FDA Application:
    NDA205596
    Drug:
    Noxafil
    Active Ingredients:
    Posaconazole
    • ...• Noxafil oral suspension 40 mg per mL (3) HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use...
    • ...FULL PRESCRIBING INFORMATION: CONTENTS* 1 2 3 4 5 6 7 INDICATIONS AND USAGE 1.1 Prophylaxis of Invasive Aspergillus and Candida Infections 1.2...

  6. Letter

    Action date:
    FDA Application:
    NDA205596
    Drug:
    Noxafil
    Active Ingredients:
    Posaconazole
    • ...DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Silver Spring MD 20993 NDA 022003/S-018, S-020 NDA 205053/S-002, S-004 NDA...
    • ...NDA 022003/S-018, S-020 NDA 205053/S-002, S-004 NDA 205596/S-001, S-003 Page 2 added and separate tables for compatible diluents and compatible drugs...

  7. Label

    Action date:
    FDA Application:
    NDA205596
    Drug:
    Noxafil
    Active Ingredients:
    Posaconazole
    • ...• Noxafil oral suspension 40 mg per mL (3) HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use...
    • ...FULL PRESCRIBING INFORMATION: CONTENTS* 1 2 3 4 5 6 7 INDICATIONS AND USAGE 1.1 Prophylaxis of Invasive Aspergillus and Candida Infections 1.2...

  8. Letter

    Action date:
    FDA Application:
    NDA205596
    Drug:
    Noxafil
    Active Ingredients:
    Posaconazole
    • ...DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Silver Spring MD 20993 NDA 022003/S-018, S-020 NDA 205053/S-002, S-004 NDA...
    • ...NDA 022003/S-018, S-020 NDA 205053/S-002, S-004 NDA 205596/S-001, S-003 Page 2 added and separate tables for compatible diluents and compatible drugs...

  9. Administrative Document & Correspondence

    Action date:
    FDA Application:
    NDA205596
    Drug:
    Noxafil
    Active Ingredients:
    Posaconazole
    • ...CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 205596Orig1s000 ADMINISTRATIVE and CORRESPONDENCE DOCUMENTS...
    • ...EXCLUSIVITY SUMMARY NDA # 205596 SUPPL # HFD # Trade Name Noxafil Injection, 18 mg/mL Generic Name Posaconazole Applicant Name Merck Sharp & Dohme...

  10. Approval Letter

    Action date:
    FDA Application:
    NDA205596
    Drug:
    Noxafil
    Active Ingredients:
    Posaconazole
    • ...CENTER FOR DRUG EVALUATION AND RESEARCH Approval Package for: APPLICATION NUMBER: 205596Orig1s000 Trade Name: Noxafil Generic Name: Posaconazole...
    • ...CENTER FOR DRUG EVALUATION AND RESEARCH 205596Orig1s000 CONTENTS Reviews / Information Included in this NDA Review. Approval Letter Other Action...